SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Date of report (Date of earliest event reported) February 24, 2014

 

 

NANOVIRICIDES, INC.
(Exact Name of Registrant as Specified in Its Charter)

 

 

Nevada 000-1379006 76-0674577
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
   
   

135 Wood Street, Suite 205

West Haven, Connecticut

 06516
(Address of Principal Executive Offices) (Zip Code)

 

 

(203) 937-6137
(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 8.01.Other Events.

 

From February 18, 2014 to February 20, 2014, the Registrant’s President and Chairman Dr. Anil Diwan purchased an aggregate of 50,000 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) in open market transactions. On February 25, 2014, Dr. Diwan repaid $83,900 to the Company as a result of the “short term profits” accrued from the sale of Common Stock at a higher price and the later purchase at a lower price.

 

Dr. Diwan originally purchased certain shares of Common Stock in February, 2013. Subsequently, Dr. Diwan sold a portion of these shares as reported on October 21, 2013. Dr. Diwan purchased 50,000 shares of Common Stock, as reported on a Form 4 filed with the Securities and Exchange Commission on February 24, 2014. Since this repurchase fell within the limitations of Section 16(b) of the Securities and Exchange Act of 1934, which relates to “short term sales” by “insiders” of a public company, Dr. Diwan disgorged the resulting net profits of $83,900 on February 25, 2014.

 

 

Item 9.01Financial Statement and Exhibits.

 

99.1Press Release dated February 26, 2014

 

 
 

 

SIGNATURES

 

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.

 

 

  NANOVIRICIDES, INC.  
       
       
Date: February 26, 2014 By:  /s/ Eugene Seymour, MD  
 

Name: Eugene Seymour

Title: Chief Executive Officer

  

 

 
 

 

INDEX OF EXHIBITS

 

Exhibit Number   Description
     
99.1   Press Release February 26, 2014